U.S. flag

An official website of the United States government

GTR Home > Tests > IDH1 IDH2 Individual Marker, Brain Cancer

Overview

Test order codeHelp: Brain Cancer Profile

Test name

Help

IDH1 IDH2 Individual Marker, Brain Cancer (IDH)

Purpose of the test

Help

This is a clinical test intended for Help: Prognostic

Condition

Help

Loading data ......

Click Indication tab for more information.

How to order

Help

81120 and/or 81121
Order URL Help: http://www.gopathlabs.com/contact_us/

Specimen source

Fresh tissue
Frozen tissue
Paraffin block

Methodology

Help
Molecular Genetics
CSequence analysis of the entire coding region
PCR
  • ABI9700 GeneAmp PCR system

Summary of what is tested

Loading data ......

Click Methodology tab for more information.

Clinical utility

Help

Not provided

Clinical validity

Help

A total of 4 High Molecular Weight DNA samples and 6 FFPE specimens were used for this study. All six FFPE specimens were extracted using our manual DNA extraction manual procedure and all ten samples were sequenced by conventional sequencing. The High Molecular Weight DNA samples were obtained from a supply company, which had internally validated the presence or absence of intended mutation, and the six FFPE specimens are previous clinical samples test by Reference Laboratory 1. The sequencing results from GoPath Laboratory were compared with the results from both reference facilities. Results from this study demonstrated 100% correlation with reference laboratory results. Furthermore, this assay correctly identified all R132 IDH1 and R140 and R172 IDH2 mutations from all DNA and FFPE specimens.

Citations

Not provided

Test services

Help
  • molecular genomic testing

Practice guidelines

  • NCCN, 2023
    NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesĀ®) Central Nervous System Cancers, 2023
  • NICE, 2021
    UK NICE Guideline NG99, Brain tumours (primary) and brain metastases in over 16s, 2021
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.